Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportIn vitro and In vivo Oncology

Fibroblast Activation Protein (FAP) as a Target for Radioligand Therapy in Glioblastoma

Pauline Jeanjean, Samantha Kwock, Christopher Tse, Timothy Cloughesy, Johannes Czernin, Giuseppe Carlucci, David Nathanson, Christine Mona and Elie Besserer-Offroy
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4050;
Pauline Jeanjean
1UCLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Kwock
2University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Tse
2University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Cloughesy
2University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
3Ahmanson Translational Theranostics Division, Pharmacology, University of California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Carlucci
3Ahmanson Translational Theranostics Division, Pharmacology, University of California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Nathanson
2University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Mona
3Ahmanson Translational Theranostics Division, Pharmacology, University of California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elie Besserer-Offroy
4Ahmanson Translational Theranostics Division, University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

4050

Introduction: Glioblastomas (GBM) are grade IV gliomas and the most aggressive, infiltrative, and fatal type of brain cancer. GBM 2- and 5-year survival rates are 18% and 4%, respectively, after surgical resection combined with chemo- and radiotherapy. Despite intensive research efforts leading to various pharmacologic approaches, a cure has remained elusive. Indeed, no GBM-targeted agents have been approved by the FDA in the past decade. Recently, fibroblast activation protein (FAP) has emerged as a new therapeutic target. FAP is selectively expressed by cancer-associated fibroblasts (CAF). In GBM, FAP is expressed both by CAFs and tumor cells. Radiolabeled small molecules targeting FAP were recently investigated for their use as pan-cancer theranostics agents. The objective of this study was to define FAP expression in GBM tumors using RNA-Seq and immunohistochemistry as well as investigate the effects of FAP-targeted radioligand therapy in a murine model of GBM.

Methods: FAP expression was quantified using RNA-Seq and immunohistochemistry on purified-GBM samples acquired from patients admitted for surgery at UCLA-Ronald Reagan Medical Center, as well as matching patient-direct orthotopic xenograft and gliomaspheres. RNA-Seq results were correlated with data available from the TCGA GBM study. We used U87MG, a glioblastoma-derived cell line known to express FAP as a xenograft model for radioligand therapy. NSG mice were implanted with U87MG cells subcutaneously and tumors were allowed to grow. FAP expression by tumors was assessed by 68Ga-FAPi-46 imaging when tumors reached around 100 mm3. When tumors reached 206 ± 75 mm3, mice were randomized into four treatment groups and treated as follows: (1) vehicle, (2) 5 mg/kg temozolomide, (3) 55 MBq 177Lu-FAPi-46, and (4) 5 mg/kg temozolomide and 55 MBq 177Lu-FAPi-46.

Results: FAP expression showed a heterogeneous expression pattern across our purified-GBM samples that correlates with RNA-Seq data available in the TCGA database. Additionally, FAP expression was conserved in matching xenografts and gliomaspheres. A high expression of FAP was observed in 30-35% of patients. Immunohistochemistry staining for FAP in matching patient and PDX tissues showed an expression of FAP by tumor cells and in pericytes at the periphery of blood vessels as previously shown. In our model, we first confirmed that U87MG tumors expressed FAP by PET imaging with an average FAPi SUVmax of 5.05 ± 0.19. Mice treated with a single injection of 177Lu-FAPi-46 showed a delay in tumor growth compared to vehicle-treated animals. Treatment with temozolomide induced a delay in tumor growth of 38 days. The combination of 177Lu-FAPi-46 and temozolomide did not show a difference in tumor growth when compared to temozolomide alone. Finally, median survival was increased from 16 to 25 days after treatment with 177Lu-FAPi-46 alone (p < 0.05), and from 44 to 51 days for temozolomide and the combination of temozolomide and 177Lu-FAPi-46, respectively.

Conclusions: As FAP is expressed by both tumor cells and the tumor microenvironment in GBM, FAP-targeted radioligand therapy can act on these two tumor compartments. Our results suggest that 177Lu-FAPi-46 could be of potential interest for GBM theranostics and that the use of alpha emitters can further improve the effect of radioligands targeting FAP in GBM. The preliminary results of combining FAP radioligand therapy and temozolomide did not show added benefits and different treatment paradigms must be assessed. Finally, we confirmed that FAP expression is conserved from patient samples to PDX and gliomaspheres, allowing the use of these types of samples for preclinical evaluation of FAP radioligands in orthotopic GBM models.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fibroblast Activation Protein (FAP) as a Target for Radioligand Therapy in Glioblastoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Fibroblast Activation Protein (FAP) as a Target for Radioligand Therapy in Glioblastoma
Pauline Jeanjean, Samantha Kwock, Christopher Tse, Timothy Cloughesy, Johannes Czernin, Giuseppe Carlucci, David Nathanson, Christine Mona, Elie Besserer-Offroy
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4050;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibroblast Activation Protein (FAP) as a Target for Radioligand Therapy in Glioblastoma
Pauline Jeanjean, Samantha Kwock, Christopher Tse, Timothy Cloughesy, Johannes Czernin, Giuseppe Carlucci, David Nathanson, Christine Mona, Elie Besserer-Offroy
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4050;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data
  • Google Scholar

More in this TOC Section

  • Mesoporous carbon nanotubes radiolabeled with 99mTc: preparation, surface chemistry and distribution study in HepG2 cells in vitro and healthy mice in vivo
  • Positron Emission Tomography of CD33 positive tumors using 89Zr-lintuzumab
  • Development of Fibroblast Activation Protein Inhibitor-based dimeric radiotracers with Improved Tumor Uptake and Retention
Show more In vitro and In vivo Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire